EMA Probe Into Paternal Valproate Exposure Risk Continues After ‘Errors’ Found In Study
Executive Summary
Initial results from a study indicate that children born to men taking valproate medicines are at an increased risk of having neurodevelopmental disorders, but “important limitations” and “errors” with the data highlight the need for further analysis.
You may also be interested in...
Don’t Use Topiramate In Pregnancy Unless No Other Drug Is Available, Says EU Drug Safety Committee
The European Medicines Agency’s pharmacovigilance committee said its safety review of topiramate took account of available data including three recent observational studies.
French Agency Faces Manslaughter Charges Over Valproate Birth Defects
The medicines regulator, ANSM, says it has been working to limit women’s exposure to the drug.
Sanofi Faces Charges Over Valproate Birth Defects
In a case that has parallels with that of Servier’s diabetes drug Mediator, Sanofi has been indicted over its alleged lack of transparency over the birth defects associated with use of its valproate drug in pregnant women.